1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

24 Sep 2019
Admin
News Article

Xbiotech Announces Granting Of Canadian Patent For Treatment Of Dermatological Pathologies

Boehringer Ingelheim And Inflammasome Therapeutics Inc. (Inflammasome) Today Announced They Have Entered Into A Co-Development And License Agreement To Develop Up To Three Therapies For Patients With Retinal Diseases. By Combining Inflammasome’S Unique Intravitreal (Ivt) Drug Delivery Technologies With Boehringer Ingelheim’S Compounds From Its Retinal Disease Pipeline Portfolio, Boehringer Ingelheim Aims To Develop Novel Therapies For Retinal Diseases.In 2019 There Were An Estimated 82 Million Patients In The Seven Key Countries (U.S., Japan, Germany, U.K., Spain, Italy, France) Affected By One Of The Three Major Forms Of Retinal Disease: Age Related Macular Degeneration (Amd), Diabetic Retinopathy (Dr), And Diabetic Macular Edema (Dme). Globally, The Prevalence Rates Of These And Other Retinal Diseases Are Expected To Increase Over The Next 10 Years Primarily Due To Aging Populations And The Global Diabetes Epidemic. Despite Therapeutic Advances In Some Disease Areas During The Past Years, The Real World Results Are Poor, And There Are No Or Only Limited Treatment Options In Many Areas, Resulting In An Overall High Unmet Need. The Collaboration Between Boehringer Ingelheim And Inflammasome Aims To Address This Challenge By Using Inflammasome’S Technology To Deliver Therapeutics In A Biodegradable Gel Formulation Into The Eye.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!